The results were definitive. In the first head-to-head randomized controlled trial comparing the two dominant GLP-1 medications, tirzepatide (Zepbound/Mounjaro) produced 20.2% mean body weight loss versus 13.7% for semaglutide (Wegovy) over 72 weeks.

20.2%
Mean body weight loss with tirzepatide vs 13.7% for semaglutide in the SURMOUNT-5 head-to-head trial (72 weeks, N=751).
Source: SURMOUNT-5 Trial, NEJM 2026

The Dual-Receptor Advantage

Tirzepatide's superiority stems from its dual mechanism. Where semaglutide activates only the GLP-1 receptor, tirzepatide activates both GLP-1 and GIP receptors—producing enhanced satiety, improved insulin sensitivity, and greater fat mobilization.

SURMOUNT-5 enrolled 751 adults with BMI ≥30 (or ≥27 with comorbidities) across 95 sites. Both drugs were titrated to maximum approved doses. The 6.5 percentage-point gap was statistically significant (p<0.001) and clinically meaningful.

Beyond the Scale

Secondary endpoints favored tirzepatide across the board: greater waist circumference reduction, superior HbA1c improvement, better lipid panel changes. The proportion achieving ≥15% weight loss was 55% for tirzepatide versus 29% for semaglutide.

Sponsored · Lion MD

Losing Muscle on Your GLP-1? There Is a Better Way.

Physician-led protocols preserving lean mass. Quarterly labs, protein Rx, resistance training plans.

Learn More →

What This Means for Patients

For patients and physicians choosing between the two, SURMOUNT-5 provides the clearest guidance yet: tirzepatide is more effective for weight loss. However, the choice involves more than efficacy:

  • Cost: Zepbound ($550/mo) vs Wegovy ($675/mo)—tirzepatide is actually cheaper
  • Availability: Semaglutide has broader insurance coverage and longer market presence
  • Side effects: GI side effects were comparable; tirzepatide showed slightly higher nausea rates during titration
  • Cardiovascular data: Semaglutide has the SELECT trial (20% MACE reduction); tirzepatide's CV outcomes trial (SURPASS-CVOT) is still ongoing
Clinical Perspective

SURMOUNT-5 settles the efficacy question. But the most important variable in patient outcomes is not which GLP-1 they take—it is whether they receive comprehensive care around it. A patient on semaglutide with proper lab monitoring, protein targets, and resistance training will outperform a patient on tirzepatide who got a prescription and nothing else.